home FAQ email sign-up search contact us
Headlines Email Alert Sign-up
HealthCast Calendar
Daily Reports Health Poll Search
Issue Spotlight
<a href="http://www.kaisernetwork.org/daily_reports/rep_index.cfm"><img src="http://www.kaisernetwork.org/images/index_flash_headlines.gif" width="437" height="42" border=0></a>

AIDS 2008: Time to Deliver
Home

Guide to Webcast Coverage

Daily Roundup

Newsmaker Interviews

Mexico City Notebook

Conference Materials

 

This conference only
Related Resources
  > AIDS2008.org

  > Kaiser Family Foundation - KFF.org
  > kaisernetwork.org
  > kaiserEDU.org
  > GlobalHealthFacts.org
  > GlobalHealthReporting.org
  > Previous kaisernetwork.org AIDS Conference Coverage
  > Clinical Care Options

XVII International AIDS Conference: August 3-8, 2008

Newer Antiretroviral Agents
8/5/2008
Mexico City

  Email this webcast

For more information on this session, including access to speaker presentations, please see the conference Programme-at-a-Glance page.

 

Full version:

Video
Transcript
Podcast

** Please note: there is intermittent audio for the first 1 minute 30 seconds of the video. We apologize for any inconvenience.



Speakers for this session:

  Co-Chairs
 
  Introduction and Background

Sharon Walmsley
Assistant Director, Immunodeficiency Clinic
Toronto Hospital



Abstract
 
  Sustained Antiretroviral Efficacy of Raltegravir as Part of Combination ART in Treatment-Naive HIV-1 Infected Patients: 96-Week Data

Martin Markowitz
Principal Investigator, Aaron Diamond Professor
Aaron Diamond AIDS Research Center



Abstract
 
  A Prospective, Randomized, Open Label Trial of Efavirenz Versus Lopinavir/Ritonavir Based HAART Among Antiretroviral Therapy Naïve, HIV Infected Individuals Presenting for Care with CD4 Cell Counts <200/mm3 in Mexico

Juan Sierra Madero
Head, HIV Clinic, Instituto Nacional de Ciencias Medicas y Nutricion
Professor of HIV Medicine, Universidad Nacional Autonoma de Mexico



Abstract
 
  Resistance Profile of Patients Failing First Line ART in Malawi When Using Clinical and Immunologic Monitoring

Mina Hosseinipour
University of North Carolina (UNC) Project



Abstract
 
  Safety Profile of Apricitabine, A Novel NRTI, During 24-Week Dosing in Experienced HIV-1 Infected Patients

Susan Cox
Head of Development
Avexa



Abstract


 

EMAIL ALERTS
Sign up for email alerts and stay informed about upcoming HealthCasts, and the latest health policy issues, news and events.
 
FAQS
More...
 
CONTACT US
Contact us by email with any comments, problems, suggestions.
Call the kaisernetwork.org Help Desk at 202-347-5270.
...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ......


About Us     Privacy Policy      Help      Site Map